US Patent Issued to Shanghai Kangabio on Nov. 18 for "Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof" (Chinese, American Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,337, issued on Nov. 18, was assigned to Shanghai Kangabio Co. Ltd. (Shanghai).

"Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof" was invented by Yang-Xin Fu (Dallas), Hua Peng (Beijing) and Diyuan Xue (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides novel fusion proteins of Interleukin 12 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy)."

The patent was filed on April 24, 2019, under Application No. 17/049,021.

*For further inform...